Abstract
Diffuse glioma is the deadliest form of brain cancer, and the median survival of grade IV glioma (glioblastoma, GBM) is no more than 2 years even with maximal surgical resection followed by radiotherapy and chemotherapy, which are now the standard of care for GBM. Glioma shares common characteristics with most malignant tumours, such as invasiveness, rapid progression, resistance to various therapies and inevitable recurrence, while it also has its own unique features, such as high aggressiveness and immunotherapy resistance, which can be, respectively, attributed to epithelial-mesenchymal transition (EMT) and the immunosuppressive microenvironment. Here, we calculated the EMT score of glioma using The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA) and the Gene Expression Omnibus (GEO) datasets and validated its prognostic value. Then, we investigated its role in the glioma immune microenvironment, identified the enriched EMT-related immune genes and determined their specific biological functions in glioma. Furthermore, clinical relevance analysis showed the translational value of these EMT-related immune genes. In short, our findings reveal a critical link between EMT and the glioma immune microenvironment and offer important clues for further investigation of the underlying molecular mechanism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akalay I, Janji B, Hasmim M et al (2013) Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 73:2418–2427. https://doi.org/10.1158/0008-5472.Can-12-2432
Anido J, Sáez-Borderías A, Gonzàlez-Juncà A et al (2010) TGF-beta receptor inhibitors target the CD44(high)/Id1(high) Glioma-initiating cell population in human Glioblastoma. Cancer Cell 18:655–668. https://doi.org/10.1016/j.ccr.2010.10.023
Ariza A et al (1995) Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Hum Pathol 26:1144–1147. https://doi.org/10.1016/0046-8177(95)90278-3
Barbie DA, Tamayo P, Boehm J et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108–112. https://doi.org/10.1038/nature08460
Bauer HC, Krizbai IA, Bauer H, Traweger A (2014) "you shall not pass"-tight junctions of the blood brain barrier. Front Neurosci 8:392. https://doi.org/10.3389/fnins.2014.00392
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Ceccarelli M, Barthel F, Malta T et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563 https://doi.org/10.1016/j.cell.2015.12.028
Chongsathidkiet P, Jackson C, Koyama et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24:1459–1468. https://doi.org/10.1038/s41591-018-0135-2
De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97–110. https://doi.org/10.1038/nrc3447
Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA (2017) Epithelial-to-Mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res 77:3982–3989. https://doi.org/10.1158/0008-5472.Can-16-3292
Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20:69–84. https://doi.org/10.1038/s41580-018-0080-4
Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937
Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014–1022. https://doi.org/10.1038/ni.2703
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for immunotherapy of cancer 6:8. https://doi.org/10.1186/s40425-018-0316-z
Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clinical cancer research : an official journal of the American Association for Cancer Research 17:5473–5480. https://doi.org/10.1158/1078-0432.Ccr-11-0774
Hambardzumyan D, Gutmann DH, Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19:20–27. https://doi.org/10.1038/nn.4185
Hilf N, Kuttruff-Coqui S, Frenzel K et al (2019) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565:240–245. https://doi.org/10.1038/s41586-018-0810-y
Hsu DS, Wang H-J, Tai S-K et al (2014) Acetylation of snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. Cancer Cell 26:534–548. https://doi.org/10.1016/j.ccell.2014.09.002
Ishimoto T, Oshima H, Oshima M et al (2010) CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 101:673–678. https://doi.org/10.1111/j.1349-7006.2009.01430.x
Ito H, Nakashima H, Chiocca EA (2019) Molecular responses to immune checkpoint blockade in glioblastoma. Nat Med 25:359–361. https://doi.org/10.1038/s41591-019-0385-7
Jackson CM, Choi J, Lim M (2019) Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol 20:1100–1109. https://doi.org/10.1038/s41590-019-0433-y
Jijiwa M, Demir H, Gupta S et al (2011) CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 6:e24217. https://doi.org/10.1371/journal.pone.0024217
Kerkar SP, Restifo NP (2012) Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 72:3125–3130. https://doi.org/10.1158/0008-5472.Can-11-4094
Keskin DB, Anandappa A, Sun J et al (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565:234–239. https://doi.org/10.1038/s41586-018-0792-9
Kudo-Saito C, Shirako H, Ohike M, Tsukamoto N, Kawakami Y (2013) CCL2 is critical for immunosuppression to promote cancer metastasis. Clinical & experimental metastasis 30:393–405. https://doi.org/10.1007/s10585-012-9545-6
Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y (2009) Cancer metastasis is accelerated through immunosuppression during snail-induced EMT of cancer cells. Cancer Cell 15:195–206. https://doi.org/10.1016/j.ccr.2009.01.023
Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168:670–691. https://doi.org/10.1016/j.cell.2016.11.037
Lim M, Xia Y, Bettegowda C, Weller M (2018) Current state of immunotherapy for glioblastoma nature reviews. Clin Oncol 15:422–442. https://doi.org/10.1038/s41571-018-0003-5
Liu Z, Kuang W, Zhou Q, Zhang Y (2018) TGF-beta1 secreted by M2 phenotype macrophages enhances the stemness and migration of glioma cells via the SMAD2/3 signalling pathway. Int J Mol Med 42:3395–3403. https://doi.org/10.3892/ijmm.2018.3923
Lu KV, Chang JP, Parachoniak C et al (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21–35. https://doi.org/10.1016/j.ccr.2012.05.037
McGranahan T, Therkelsen KE, Ahmad S, Nagpal S (2019) Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol 20:24 https://doi.org/10.1007/s11864-019-0619-4
Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480–489. https://doi.org/10.1038/nature10673
Miao Y-R, Zhang Q, Lei Q, Luo M, Xie G-Y, Wang H, Guo A-Y (2019) ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy bioRxiv. Adv Sci. https://doi.org/10.1101/872184
Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR (2019) Genetic and molecular epidemiology of adult diffuse glioma nature reviews. Neurology 15:405–417. https://doi.org/10.1038/s41582-019-0220-2
Monaco G, Lee B, Xu W et al (2019) RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cell Rep 26:1627–1640 e1627. https://doi.org/10.1016/j.celrep.2019.01.041
Mooney KL, Choy W, Sidhu S et al (2016) The role of CD44 in glioblastoma multiforme. J Clin Neurosci 34:1–5. https://doi.org/10.1016/j.jocn.2016.05.012
Naor D (2016) Editorial: interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and Cancer. Front Immunol 7:39. https://doi.org/10.3389/fimmu.2016.00039
Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination Seminars in cancer biology 18:260–267 https://doi.org/10.1016/j.semcancer.2008.03.015
Nieto MA, Huang RY, Jackson RA, Thiery JP (2016) EMT: 2016. Cell 166:21–45. https://doi.org/10.1016/j.cell.2016.06.028
Noman MZ, Janji B, Abdou A et al (2017) The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology 6:e1263412. https://doi.org/10.1080/2162402x.2016.1263412
Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273. https://doi.org/10.1038/nrc2620
Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D (2017) Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. https://doi.org/10.7554/eLife.26476
Sangaletti S, Tripodo C, Santangelo A et al (2016) Mesenchymal transition of high-grade breast carcinomas depends on extracellular matrix control of myeloid suppressor cell activity. Cell Rep 17:233–248. https://doi.org/10.1016/j.celrep.2016.08.075
Scheel C, Eaton EN, Li SH-J et al (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145:926–940. https://doi.org/10.1016/j.cell.2011.04.029
Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14:611–629. https://doi.org/10.1038/nrclinonc.2017.44
Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19:1438–1449. https://doi.org/10.1038/nm.3336
Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S (2017) New insights into the role of EMT in tumor immune escape. Mol Oncol 11:824–846. https://doi.org/10.1002/1878-0261.12093
Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890. https://doi.org/10.1016/j.cell.2009.11.007
Weller M, Le Rhun E (2019) Immunotherapy for glioblastoma: quo vadis? Nat Rev Clin Oncol 16:405–406. https://doi.org/10.1038/s41571-019-0195-3
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507. https://doi.org/10.1056/NEJMra0708126
Woroniecka K, Chongsathidkiet P, Rhodin K et al (2018) T-cell exhaustion signatures vary with tumor type and are severe in Glioblastoma. Clin Cancer Res 24:4175–4186. https://doi.org/10.1158/1078-0432.Ccr-17-1846
Yoshihara K, Shahmoradgoli M, Martínez E et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612. https://doi.org/10.1038/ncomms3612
Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284–287. https://doi.org/10.1089/omi.2011.0118
Acknowledgements
We thank the investigators and patients who participated in CGGA, TCGA and GEO for providing data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors have no conflicts of interest to report.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ning, W., Qiu, Z., Ji, X. et al. The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment. J Mol Neurosci 70, 1501–1511 (2020). https://doi.org/10.1007/s12031-020-01583-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-020-01583-y